1 Analytical Sensitivity of the SalivaDirect[™] Assay on the Liberty16 for

2 detecting SARS-CoV-2 B.1.1.529 ("Omicron")

- 3 Yen Pei Tan^{1,*}, Mila Al-Halbouni¹, Ching-Huan Chen¹, David B. Hirst¹, Paul J.
- 4 Pickering¹
- ⁵ ¹ Ubiquitome Limited, 1/234A Bush Road, Rosedale, Auckland, New Zealand
- 6 *Corresponding author's e-mail: <u>e.tan@ubiquitomebio.com</u>
- 7
- 8 Keywords
- 9 SARS-CoV-2; Omicron variant; SalivaDirect; Saliva Testing; Liberty16
- 10

11 Abstract

The newly emerged Omicron variant of SARS-CoV-2 has numerous mutations that 12 are not found in other variants of concern (VOCs). Despite acquiring extended 13 functions in adapting to the host-cell environment, the viral genetic variation exerts a 14 potential negative impact on a molecular test, which in turn, compromises public health 15 and safety. The Liberty16 has been clinically validated as a flexible and accessible 16 device system for running the affordable SalivaDirect[™] real time PCR detection assay 17 for SARS-CoV-2 especially in low resource settings. Preliminary, based on in-silico 18 sequence analysis, we found that Omicron's mutation at position 28,311 overlaps with 19 the CDC 2019-nCoV_N1 probe binding region. In order to verify the performance of 20 CDC 2019-nCoV-N1 primers-probe set in detecting the Omicron variant of SARS-21 CoV-2, plasmids containing Wuhan/WH01/2019 (wild-type) and B.1.1.529 (Omicron) 22 sequences were serially diluted and subsequently directed for SalivaDirect[™] RT-23 qPCR detection on Liberty16 using commercially procured reagents. Our findings 24 provide analytical support for reports that the mutations in the Omicron variant have 25 little or no impact on SalivaDirect[™] assay in terms of amplification efficiency and 26 detection sensitivity using either standard and the recently reported fast Liberty16 27 SalivaDirect[™] thermal cycling protocols. 28

29

30 Introduction

The first known confirmed B.1.1.529 infection was from a specimen collected on 9

November 2021. Based on the evidence presented indicative of a detrimental change

33 ino CON Ino to map identistogy hand not reer aprile pisce of view factions nor be South undericated World

Health Organization (WHO) has immediately designated B.1.1.529 as a variant of concern (VOC), named Omicron (Figure 1A) (WHO, 2021). Since then, Omicron has spread rapidly through the world and caused the global case count to exceed 1 million daily cases (Singhal, 2022; Taylor, 2022).

38

The Omicron variant possesses a large number of new mutations which have not been 39 observed in other strains (Table 1) (Hadfield et al., 2018). Most worrying, over two-40 thirds of these mutations were found on its spike protein. Like other coronaviruses, the 41 42 spike protein of SARS-CoV-2 is well recognized as a key component to initiate binding with the host-cell angiotensin-converting enzyme 2 (ACE2) and establish an infection 43 (Zhou et al., 2020). Changes on the Omicron's spike protein are particularly relevant 44 to increase its affinity for ACE2 receptor and impact host immunity recognition 45 (Cameroni et al., 2021; Redd et al., 2021), though the detailed mechanisms regarding 46 47 viral pathogenicity and transmissibility remain largely unclear.

48

Apart from that, the presence of genetic variation in the Omicron variant exerts a 49 potential negative impact on molecular tests which were designed based on the origin 50 51 sequence. For example, Omicron is highly associated with S-gene target failure (SGTF) on the Taqpath RT-PCR test (Torjesen, 2021). Also, according to FDA's 52 analysis to date, a single target test developed by Meridian Bioscience, Inc. is already 53 known to fail to detect the SARS-CoV-2 Omicron variant. We found that Omicron's 54 mutation at position 28,311 overlaps with the CDC 2019-nCoV N1 probe binding 55 region (Figure 1B). Viral detection using the SalivaDirect[™] protocol is solely reliant on 56 the N1 primer-probe (Vogels et al., 2021), and thus, a mutation in this region is 57 potentially impacting on the assay's sensitivity. 58

59

In the presented study, we aimed to assess the impact of the C28311T mutation on
 analytical PCR performance with the Liberty16 device using the SalivaDirect[™]
 protocol and to verify the assay's sensitivity in detecting the Omicron variant.

63

64 Materials and Methods

65 Assay's Sensitivity in Detecting SARS-CoV-2 Wuhan/WH01/2019 and B.1.1.529

The partial N gene sequences of SARS-CoV-2 Wuhan/WH01/2019 (wild-type) and 66 B.1.1.529 (Omicron) were generated and cloned into pUC57 at EcoRV/BamHI site 67 (Genscript Biotech Corporation). These plasmids were used to prepare serially diluted 68 analytes for subsequent RT-qPCR detection accordingly to a single-plex version of the 69 SalivaDirect[™] protocol run on the Liberty16 System (Yolda-Carr et al., 2022) by using 70 FAM-labelled CDC 2019-nCoV-N1 primers-probe set [Integrated DNA Technologies 71 2019-nCoV RUO Kit (10006713)] and New England Biolabs Luna Probe One-Step 72 RT-qPCR Mix with UDG (M3019). Additionally, both the standard (Vogels et al., 2021) 73 74 (95°C, 10s; 55°C, 30s) and fast cycling protocols (Yolda-Carr et al., 2022) (95°C, 2s; 75 55°C, 5s) were tested.

76

77 Robustness Test

The limit of detection (LoD) for the Liberty16 system was previously confirmed at 12
copies/µL (Yolda-Carr et al., 2022). In the presented study, 2x LoD (24 copies/µL) of
plasmid DNA were used for a robustness study. Detection sensitivity was evaluated
with 20 replicates per condition.

82

83 Statistical Analysis

The statistical analysis was conducted with a statistics computer software, GraphPad Prism 9.3.1. Differences between the standard and fast cycling protocols were assessed by testing slope differences and Bland-Altman plot.

87

88 **Results**

The CDC 2019-nCoV-N1 primers-probe set can detect the Omicron N1 target despite the C28311T mutation.

Plasmids containing Wuhan/WH01/2019 (wild-type) and B.1.1.529 (Omicron) sequences were serially diluted into 6-log series, from approximately 5×10^5 to 5 copies/µL, and subsequently directed for SalivaDirectTM RT-qPCR detection using commercially procured materials. As shown in Figure 2A, the N1 targets were able to be detected across the 6-log dilution series of the mutant and wild-type plasmid DNA. Comparative analysis of these two amplification plots showed no significant difference between the slopes (P = 0.7963).

98

Omicron's N gene can be efficiently detected by using either SalivaDirect[™] 99 standard or fast cycling protocols on Liberty16. 100

101

Next, to assess the agreement between SalivaDirectTM standard protocol and the most 102 recent updated fast cycling protocol on Liberty16, a preliminary study using duplicate 103 samples across a 5-log dilution series (from approximately 3×10⁵ to 30 copies/µL) and 104 a considerably low DNA template concentration (~3 copies/µL) was conducted. The 105 same samples were run in parallel on Liberty16 devices with different thermal cycling 106 107 protocols. As expected, the N1 targets were able to be detected across 5-log dilution series of the mutant and wild-type plasmid DNA using either of the two protocols with 108 no significant difference in amplification (Figure 2B and 2C). Remarkably, comparison 109 analysis showed no significant difference between these two protocols in detecting 110 Omicron's N1 gene (Figure 2D). The data points plotted in the quantile-quantile plot 111 (QQ plot) showed approximately on a straight line, indicating a high positive correlation 112 (Figure 2E). And statistically, high correlation coefficient ($R^2 = 0.9458$) was found 113 between these two protocols in detecting either wild-type or Omicron variant of SARS-114 CoV-2 (with P < 0.0001). Hence, we concluded that both protocols worked comparably 115 116 well in detecting the Omicron variant sequence of SARS-CoV-2.

- 117
- 118

The LoD of Omicron detection is comparable to SARS-CoV-2 first isolate 119 120 Wuhan/WH01/2019.

121

The C28311T mutation did not affect the SalivaDirect[™] assay's sensitivity as 20 out 122 of 20 reactions with 2xLoD (24 copies/µL) were detected for both the wild-type and 123 mutant plasmid DNA (Figure 2E). To further assess the agreement, the Bland-Altman 124 plot was used to assess the existence of a significant bias between these two variants 125 (Figure 2F). As shown, 19/20 of the data points are within 95% limits of agreement. 126 Notably, the only disagreement was caused by an outlier data point testing on wild-127 type plasmid DNA (Figure 2E and 2F). 128

- 129
- 130
- **Conclusions** 131

Based on the presented qualitative and quantitative analysis, we conclude that the 132 Omicron C28311T mutation has little or no impact on viral detection using 133 SalivaDirect[™] assay. Our findings are similar to recent independent studies (Bei et al., 134 2021). In addition, our data further confirms that the SalivaDirect[™] assay works 135 comparably well using either standard or fast thermal cycling protocols in detecting the 136 Omicron variant sequence. As recently reported, the fast protocol takes just under one 137 hour and is expected to increase sample throughput by more than 60% (Yolda-Carr et 138 al., 2022). This analytical sensitivity study supports the use of the Liberty16 device 139 system with SalivaDirect[™] to further facilitate timely access to on-demand screening 140 for infectious respiratory diseases especially within low resource settings. 141

142

143 Aknowledgement

We thank Dr Anne Wylie for her review of this manuscript and Anne and the
SalivaDirect[™] team for their continued support for SARS-CoV-2 accessible testing
solutions for low resource settings.

147

148 Competing Interests

The authors are employees of, and received funding from, Ubiquitome Limited, the manufacturer of Liberty 16 described in the paper. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

154

155 **References:**

- World Health Organization. (2021). Classification of Omicron (B.1.1.529): SARS-CoV-2
 Variant of Concern.
- Bei, Y., Vrtis, K.B., Borgaro, J.G., Langhorst, B.W., and Nichols, N.M. (2021). The
 Omicron variant mutation at position 28,311 in the SARS-CoV-2 N gene does not
 perturb CDC N1 target detection. medRxiv, 2021.2012.2016.21267734.
- Cameroni, E., Bowen, J.E., Rosen, L.E., Saliba, C., Zepeda, S.K., Culap, K., Pinto, D.,
 VanBlargan, L.A., De Marco, A., di Iulio, J., *et al.* (2021). Broadly neutralizing antibodies
 overcome SARS-CoV-2 Omicron antigenic shift. Nature.
- Hadfield, J., Megill, C., Bell, S.M., Huddleston, J., Potter, B., Callender, C., Sagulenko,
 P., Bedford, T., and Neher, R.A. (2018). Nextstrain: real-time tracking of pathogen
 evolution. Bioinformatics *34*, 4121-4123.
- Redd, A.D., Nardin, A., Kared, H., Bloch, E.M., Abel, B., Pekosz, A., Laeyendecker, O.,
 Fehlings, M., Quinn, T.C., and Tobian, A.A. (2021). Minimal cross-over between
 mutations associated with Omicron variant of SARS-CoV-2 and CD8+ T cell epitopes
 identified in COVID-19 convalescent individuals. bioRxiv.
- Singhal, T. (2022). The Emergence of Omicron: Challenging Times Are Here Again!
 Indian J Pediatr.
- Taylor, L. (2022). Covid-19: Omicron drives weekly record high in global infections.
 BMJ *376*, o66.
- Torjesen, I. (2021). Covid-19: Omicron may be more transmissible than other variants
 and partly resistant to existing vaccines, scientists fear. BMJ *375*, n2943.
- Vogels, C.B.F., Watkins, A.E., Harden, C.A., Brackney, D.E., Shafer, J., Wang, J.,
 Caraballo, C., Kalinich, C.C., Ott, I.M., Fauver, J.R., *et al.* (2021). SalivaDirect: A
 simplified and flexible platform to enhance SARS-CoV-2 testing capacity. Med (N Y) *2*,
 263-280 e266.
- 10. Yolda-Carr, D., Thammavongsa, D.A., Vega, N., Turner, S.J., Pickering, P.J., and Wyllie,
 A.L. (2022). Evaluation of the Liberty16 Mobile Real Time PCR Device for Use With the
 SalivaDirect Assay for SARS-CoV-2 Testing. Frontiers in Cellular and Infection
 Microbiology 11.
- 11. Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., Si, H.R., Zhu, Y., Li, B.,
 Huang, C.L., *et al.* (2020). A pneumonia outbreak associated with a new coronavirus
 of probable bat origin. Nature *579*, 270-273.

188

All rights reserved. No reuse allowed without permission.



Figure 1. The emergence of Omicron variant and its particular mutation site in 2019-nCoV-N1 probe binding region. A) The Omicron variant and other major or previous variants of concern of SARS-CoV-2 depicted in a tree scaled radially by genetic distance, derived from Nextstrain on 7 December 2021; B) Partial N gene sequences of SAR-CoV-2 isolate Wuhan/WH01/2019 and the binding regions of N1 primers and probe. The mutation site, amino acid P13L or nucleotide base C28311T, of Omicron variant is highlighted in red.



Figure 2. The SalivaDirect[™] assay's sensitivity in detecting wild-type SARS-**CoV-2 and Omicron variant.** A-B) Linearity performance of SalivaDirectTM assay in detecting wild-type SARS-CoV-2 and Omicron variant using standard cycling protocol; C) Linearity performance of SalivaDirect[™] assay in detecting wild-type SARS-CoV-2 and Omicron variant using fast cycling protocol; D) Comparison of the standard SalivaDirect[™] RT-qPCR and updated fast cycling protocols on Omicron's N1 detection; E) QQ plot of the results obtained by two different cycling protocols; F) Robustness test on 2x LoD (n = 20); G) Bland-Altman plot: The agreement between wild-type and Omicron detection; Solid horizontal line shows the mean difference, dotted line shows the 95 % confidence interval of the mean difference.

Tables

Gene	Mutations
ORF1a	K856R, V1887I, S2083-, L2084I, A2710T, T3255I,
	P3395H, L3674-, S3675-, G3676-, I3758V
ORF1b	P314L, I1566V
S	A67V, H69-, V70-, T95I, G142-, V143-, Y144-,
	Y145D, N211-, L212I, G339D, S371L, S373P,
	S375F, K417N, N440K, G446S, S477N, T478K,
	E484A, Q493R, G496S, Q498R, N501Y, Y505H,
	T547K, D614G, H655Y, N679K, P681H, N764K,
	D796Y, N856K, Q954H, N969K, L981F
E	T9I
Μ	D3G, Q19E, A63T
Ν	P13L, E31-, R32-, S33-, R203K, G204R
ORF9b	P10S, E27-, N28-, A29-

Table 1. The mutation sites of Omicron variant.